The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Phase II Trial of Tideglusib in Alzheimer's Disease
Abstract
BACKGROUND: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD). OBJECTIVE: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. METHODS: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 weeks. The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints. RESULTS: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries. There were no statistically significant differences between either active and placebo arms in the efficacy variables. However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients. Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency. Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. However, given the non-linear dose response, especially in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“The clinical studies in patients with mild-to-moderate AD (NCT01350362, NCT00948259) or PSP (NCT01049399) patients treated with tideglusib were negative on the clinical outcomes [218]; however, a subgroup analysis of PSP patients showed reduced brain atrophy [219].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [218]
In the citing paper
“However, a phase 2 trial in mild to moderate AD did not demonstrate any reduction in rate of cognitive or functional decline as compared to placebo (Lovestone et al., 2015)”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Lovestone et al., 2015
In the citing paper
“Tideglusib, a small-molecule GSK3β inhibitor, failed to improve cognition in a phase 2 clinical study, and CSF levels of Aβ42, total tau, and pTau181 were not altered, resulting in failure of the trial [175,176].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [176]
In the citing paper
“In a larger phase II study, tideglusib treatment was associated with significant cognitive improvement and a reduction in CSF levels of β-secretase in a subgroup of patients with mild AD122. However, when the entire study cohort was analysed, tideglusib was found to be well tolerated but produced no significant improvements122.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [122]
In the citing paper
“Another GSK-3 inhibitor, tideglusib, did not meet phase 2 clinical endpoints in patients with mild and moderate AD.80”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [80]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,535
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 556
Palomo, V., Pérez, D. I., Roca, C., Anderson, C. J., Rodríguez‐Muela, N., Pérez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Pérez‐Castillo, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00395 · Cited by 77
The cellular basis of dendrite pathology in neurodegenerative diseases
Kweon, J. H., Kim, S., & Lee, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.1.131 · Cited by 73
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 75
Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73
Gureev, A. P., Popov, V. N., & Starkov, A. A. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113285 · Cited by 75
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 76
Peña‐Altamira, E., Prati, F., Massenzio, F., Virgili, M., Contestabile, A., Bolognesi, M. L., & Monti, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1121237 · Cited by 70
Sun, H., Zhong, Y., Zhu, X., Liao, H., Lee, J., Chen, Y., Ma, L., Ren, J., Zhao, M., Tu, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10690 · Cited by 70
Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
Ye, J., Wan, H., Chen, S., & Liu, G. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385847 · Cited by 74
Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice
Ricke, K. M., Cruz, S. A., Qin, Z., Farrokhi, K., Sharmin, F., Zhang, L., ZASLOFF, M. A., Stewart, A. F. R., & Chen, H. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2120-19.2019 · Cited by 71
Martínez‐González, L., Gonzalo‐Consuegra, C., Gómez‐Almería, M., Porras, G., de Lago, E., Martín‐Requero, Á., & Martı́nez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168975 · Cited by 68
“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 69
PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases
Jiang, X., Zhou, J., Wang, Y., Liu, X., Xu, K., Xu, J., Feng, F., & Sun, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112949 · Cited by 68
Glycogen synthase kinase-3: A potential target for diabetes
Teli, D., & Gajjar, A. K. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117406 · Cited by 66
de Matos, A. M., Macedo, M. P., & Rauter, A. P. (2017) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 68
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
Jorge-Torres, O. C., Szczęsna, K., Roa, L., Casal, C., Somermeyer, L. G., Soler, M., Velasco, C. D., Segundo, P. M. S., Petazzi, P., Sáez, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.010 · Cited by 66
Yang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63
“Tideglusib, a small-molecule GSK3 β inhibitor, failed to improve cognition in a phase 2 clinical study, and CSF levels of A β 42, total tau, and pTau181 were not altered, resulting in failure of the trial [175,176].”
BackgroundReview on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63
Turkistani, A. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Elfiky, M. M., Saad, H. M., & Batiha, G. E. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04003-z · Cited by 64
Qu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors
Wadhwa, P. K., Jain, P., & Jadhav, H. R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516153136 · Cited by 61
Alireza, M. S., Nikbakht, F., Nia, H. H., Golab, F., Khadem, Y., Barati, M., & Vazifekhah, S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102200 · Cited by 61
Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice
Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.027 · Cited by 59
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases
Gianferrara, T., Cescon, E., Grieco, I., Spalluto, G., & Federico, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220216113517 · Cited by 58
Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects
Cheng, Z., Han, T., Yao, J., Wang, K., Dong, X., Fan, Y., Huang, H., Han, M., Liao, Q., He, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116065 · Cited by 58
Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint
AlRuwaili, R., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Fetoh, M. E. A., & Batiha, G. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05113-y · Cited by 64
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 60
Matsunaga, S., Fujishiro, H., & Takechi, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190256 · Cited by 57
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Benn, C., & Dawson, L. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00242 · Cited by 59
Yadikar, H., Torres, I., Aiello, G., Kurup, M., Yang, Z., Lin, F. Y., Kobeissy, F. H., Yost, R. A., & Wang, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0224952 · Cited by 58
Aberrant regulation of the GSK‐3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy
Ranea‐Robles, P., Launay, N., Ruíz, M., Calingasan, N. Y., Dumont, M., Naudí, A., Portero‐Otín, M., Pamplona, R., Ferrer, I., Beal, M. F., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708604 · Cited by 55
Li, Z., Yin, B., Zhang, S., Lan, Z., & Zhang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115817 · Cited by 54
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 55
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)
Palomo, V., & Martínez, A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1259412 · Cited by 55
Giacomini, C., Koo, C.-Y., Yankova, N., Tavares, I. A., Wray, S., Noble, W. J., Hanger, D. P., & Morris, J. D. H. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0539-8 · Cited by 56
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 55
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 60
Tan, X., Liang, Z., Li, Y., Zhi, Y., Yi, L., Bai, S., Forest, K. H., Nichols, R. A., Dong, Y., & Li, Q. X. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112968 · Cited by 52
Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 52
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50
Kong, L.-H., Yu, C.-C., Wang, Y., Shen, F., Wang, Y., Zhou, H., & Tang, L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238620 · Cited by 51
Therapeutic Potential of Multifunctional Tacrine Analogues
Przybyłowska, M., Kowalski, S., Dzierzbicka, K., & Inkielewicz‐Stępniak, I. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180412091908 · Cited by 51
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Sobierajski, T., Małolepsza, J., Pichlak, M., Gendaszewska‐Darmach, E., & Błażewska, K. M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104032 · Cited by 48
Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
Choi, H., Cha, S. J., Lee, J., Kim, H., & Kim, K. (2020) · Brain Sciences · doi:10.3390/brainsci10100675 · Cited by 50
Machine Learning for Discovery of GSK3β Inhibitors
Vignaux, P. A., Minerali, E., Foil, D. H., Puhl, A. C., & Ekins, S. (2020) · ACS Omega · doi:10.1021/acsomega.0c03302 · Cited by 49
MiR-9-5p inhibits mitochondrial damage and oxidative stress in AD cell models by targeting GSK-3β
Liu, J., Zuo, X., Han, J., Dai, Q., Xu, H., Liu, Y., & Cui, S. (2020) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2020.1797469 · Cited by 50
Tilting MYC toward cancer cell death
Harrington, C. T., Sotillo, E., Dang, C. V., & Thomas‐Tikhonenko, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.002 · Cited by 48
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 47
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
Zhang, T., Kim, B. M., & Lee, T. H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00395-5 · Cited by 49
Chen, M., Fang, Y., Ge, Y., Qiu, S., Dworkin, L. D., & Gong, R. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103127 · Cited by 48
Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00356 · Cited by 49
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy
Palomo, V., Nozal, V., Rojas‐Prats, E., Gil, C., & Martı́nez, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15221 · Cited by 51
Rana, A. K., Rahmatkar, S. N., Kumar, A., & Singh, D. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.08.002 · Cited by 48
Treatment of epilepsy for people with Alzheimer's disease
Liu, J., Wang, L., Wu, L., & Wang, Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011922.pub2 · Cited by 46
Peña‐Altamira, E., Petralla, S., Massenzio, F., Virgili, M., Bolognesi, M. L., & Monti, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00175 · Cited by 46
Glycogen synthase kinase-3: A potential preventive target for prostate cancer management
Li, B., Thrasher, J. B., & Terranova, P. F. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.006 · Cited by 45
Disentangling tau: One protein, many therapeutic approaches
Lane‐Donovan, C., & Boxer, A. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00321 · Cited by 49
Recent developments with tau-based drug discovery
Iqbal, K., Liu, F., & Gong, C. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1445084 · Cited by 46
Targeting dementias through cancer kinases inhibition
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43
Furlotti, G., Alisi, M. A., Cazzolla, N., Dragone, P., Durando, L., Magarò, G., Mancini, F., Mangano, G., Ombrato, R., Vitiello, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01208 · Cited by 43
Synthesis of Diverse 11 C-Labeled PET Radiotracers via Direct Incorporation of [ 11 C]CO 2
Mossine, A. V., Brooks, A. F., Jackson, I. M., Quesada, C., Sherman, P. S., Cole, E. L., Donnelly, D. J., Scott, P. J. H., & Shao, X. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00163 · Cited by 43
The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer’s Disease
Hugon, J., & Paquet, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063136 · Cited by 44
Amaral, A. C. S., Perez‐Nievas, B. G., Chong, M. S. T., González‐Martínez, A., Argente‐Escrig, H., Rubio‐Guerra, S., Commins, C., Muftu, S., Eftekharzadeh, B., Hudry, E., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102058 · Cited by 44
Herrera‐Arozamena, C., Martí‐Marí, O., Estrada, M., Revenga, M. D. L. F., & Rodrı́guez-Franco, M. I. (2016) · Molecules · doi:10.3390/molecules21091165 · Cited by 42
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 42
Drug repurposing towards targeting cancer stem cells in pediatric brain tumors
Bahmad, H. F., Elajami, M. K., Zarif, T. E., Bou-Gharios, J., Abouantoun, T. J., & Abou-Kheir, W. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09840-2 · Cited by 42
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)
Roca, C., & Campillo, N. E. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1815706 · Cited by 42
Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease
Anand, K., & Sabbagh, M. N. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1075002 · Cited by 41
Jiang, X., Zhou, J., Wang, Y., Chen, L., Duan, Y., Huang, J., Liu, C., Chen, Y., Liu, W., Sun, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112751 · Cited by 39
Suzuki, N., Hatta, T., Ito, M., & Kusakabe, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00069 · Cited by 41
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 42
Menduti, G., Rasà, D. M., Stanga, S., & Boido, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592234 · Cited by 40
GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel
Alaohali, A., Salzlechner, C., Zaugg, L. K., Suzano, F. R., Martı́nez, A., Gentleman, E., & Sharpe, P. T. (2021) · Journal of Dental Research · doi:10.1177/00220345211020652 · Cited by 39
Hartz, R. A., Ahuja, V. T., Sivaprakasam, P., Xiao, H., Krause, C., Clarke, W., Kish, K., Lewis, H. A., Szapiel, N., Ramu, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00133 · Cited by 38
Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease
Chakravarthy, M., Chen, S., Dodd, P. R., & Veedu, R. N. (2017) · Theranostics · doi:10.7150/thno.21529 · Cited by 39
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 39
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 39
Antoniou, N., Prodromidou, K., Kouroupi, G., Boumpoureka, I., Samiotaki, M. K., Panayotou, G., Xilouri, M., Kloukina, I., Stefanis, L., Grailhe, R., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00278-y · Cited by 39
Atila, D., Chen, C., Lin, C., Lee, Y., Hasırcı, V., Tezcaner, A., & Lin, F. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118976 · Cited by 37
Grizzell, J. A., Patel, S. P., Barreto, G. E., & Echeverría, V. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.010 · Cited by 37
Thibault, S., Hu, W., Hirakawa, B. P., Kalabat, D. Y., Franks, T., Sung, T., Khoh‐Reiter, S., Lu, S., Finkelstein, M. B., Jessen, B. A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0734 · Cited by 38
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Baviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 36
Early Stage Glycosylation Biomarkers in Alzheimer’s Disease
Regan, P., McClean, P. L., Smyth, T. J., & Doherty, M. (2019) · Medicines · doi:10.3390/medicines6030092 · Cited by 38
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Tau, tau kinases, and tauopathies: An updated overview
Montalto, G., & Ricciarelli, R. (2023) · BioFactors · doi:10.1002/biof.1930 · Cited by 39
Osorio, R., Rodríguez‐Lozano, F. J., Toledano, M., Toledano‐Osorio, M., García‐Bernal, D., Murcia, L., & López‐García, S. (2024) · Dental Materials · doi:10.1016/j.dental.2024.07.012 · Cited by 35
Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease
Fernández‐Nogales, M., Hernández, F., Miguez, A., Alberch, J., Ginés, S., Pérez‐Navarro, E., & Lucas, J. J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv224 · Cited by 35
Guo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 37
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Kowalska, M., Wize, K., Prendecki, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224121447 · Cited by 34
Ávila, J., Pallas‐Bazarra, N., Bolós, M., Sayas, C. L., & Hernández, F. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1131269 · Cited by 36
Mathuram, T. L., Ravikumar, V., Reece, L. M., Selvaraju, K., Sasikumar, C. S., & Cherian, K. M. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.07.013 · Cited by 33
Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Александровна, П. Е., Chernyuk, D., & Борисович, Б. И. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200528162046 · Cited by 34
Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression
Cortés‐Gómez, M., Llorens‐Álvarez, E., Alom, J., del Ser, T., Ávila, J., Sáez‐Valero, J., & García‐Ayllón, M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15189 · Cited by 33
Bahmad, H. F., Chalhoub, R., Harati, H., Bou-Gharios, J., Assi, S., Ballout, F., Monzer, A., Msheik, H., Araji, T., Elajami, M. K., et al. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00162-7 · Cited by 33
Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer’s Disease
Li, M., Cai, N., Gu, L., Yao, L., Bi, D., Fang, W., Lin, Z., Wu, Y. L., Xu, H. Y., Li, H., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02389-8 · Cited by 33
Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 33
Metadata
- Authors
- Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., León, T., & del Ser, T.
- Affiliations
- University of Oxford (GB)
- Fundació ACE (ES)
- Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- Inserm (FR)
- University of Turku (FI)
- Instituto de Salud Carlos III (ES)
- Clinical Department, Noscira SA, Madrid, Spain
- Medical Department, Noscira SA, Madrid, Spain
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-03-03
- Volume
- 45
- Issue
- 1
- Pages
- 75-88
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1522284801
- Cited by
- 536
- References
- 47
- Citations by year
- 2026: 44 · 2025: 67 · 2024: 59 · 2023: 46 · 2022: 38 · 2021: 59 · 2020: 61 · 2019: 31 · 2018: 46 · 2017: 39 · 2016: 31 · 2015: 14
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10053)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tideglusib, Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Thiadiazoles, Amyloid beta-Peptides, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
